Skip to main content
Top
Published in: BMC Infectious Diseases 1/2016

Open Access 01-12-2016 | Research article

Tuberculosis treatment outcomes of six and eight month treatment regimens in districts of Southwestern Ethiopia: a comparative cross-sectional study

Authors: Abyot Asres, Degu Jerene, Wakgari Deressa

Published in: BMC Infectious Diseases | Issue 1/2016

Login to get access

Abstract

Background

A switch of continuation phase tuberculosis (TB) treatment regimen from Ethambutol (E) and Isoniazid (H) combination for 6 months (6EH) to Rifampicin (R) and Isoniazid (H) combination for 4 months (4RH) was recommended. However, the effect of the regimen switch in Ethiopian setting is not known.

Methods

A comparative cross-sectional study among 790 randomly selected new cases of TB (395 each treated with 4RH and 6EH during the continuation phase) was conducted in nine health centers and one hospital in three zones in southwestern Ethiopia. Data were abstracted from the standard unit TB register composed of standard case and treatment outcome definitions. Data were analyzed using STATA version 13 where binary logistic regression was fitted to identify independent predictors of unsuccessful treatment outcomes at 5 % significance level.

Results

Over all, 695 (88 %) of the patients had a successful treatment outcome with statistically significant difference (85.3 % vs 90.6 %, p = 0.02) among the 6HE and 4RH regimens, respectively. After adjusting for confounders, 4RH continuation phase treatment regimen adjusted odds ratio (AOR) [(95 % confidence interval (CI)) 0.55 (0.34,0.89)], age [AOR (95 % CI 1.02 (1.001,1.022)], rural residence [AOR (95 % CI) 2.1 (1.18,3.75)] Human Immunodeficiency virus (HIV) positives [AOR (95 % CI) 2.39 (1.12,5.07)] and increased weight at the end of the second month [AOR (95 % CI 0.28 (0.11,0.72)] independently predicted treatment outcome.

Conclusion

The switch of continuation phase TB treatment regimen from 6EH to 4RH has brought better treatment outcomes which imply applicability of the recommendation in high prevalent and resource constrained settings. Therefore, it should be maintained and augmented through further studies on its impact among the older, rural residents and HIV positives.
Appendix
Available only for authorised users
Literature
1.
go back to reference Hill AB. Suspended judgment. Memories of the British Streptomycin Trial in Tuberculosis. The first randomized clinical trial. Control Clin Trials. 1990;11(2):77–9.CrossRefPubMed Hill AB. Suspended judgment. Memories of the British Streptomycin Trial in Tuberculosis. The first randomized clinical trial. Control Clin Trials. 1990;11(2):77–9.CrossRefPubMed
2.
go back to reference Arandottir T. Tuberculosis and public health: Policy and principles of Tuberculosis control. Paris: International Union Against Tuberculosis and Lung Disease; 2009. Arandottir T. Tuberculosis and public health: Policy and principles of Tuberculosis control. Paris: International Union Against Tuberculosis and Lung Disease; 2009.
3.
go back to reference British Medical council. Streptomycin for treatment of pulmonary tuberculosis. Br Med J. 1948;2(4582):769–82. British Medical council. Streptomycin for treatment of pulmonary tuberculosis. Br Med J. 1948;2(4582):769–82.
5.
go back to reference WHO. Treatment of Tuberculosis: Guidelines for National Programmes. Geneva: World Health Organization; 2003. WHO. Treatment of Tuberculosis: Guidelines for National Programmes. Geneva: World Health Organization; 2003.
6.
go back to reference WHO. Guidelines for tuberculosis treatment in adults and children in national tuberculosis programmes. Geneva: World Health Organization; 1991. WHO. Guidelines for tuberculosis treatment in adults and children in national tuberculosis programmes. Geneva: World Health Organization; 1991.
7.
go back to reference World Health Organization. Treatment of tuberculosis: guidelines. Geneva: World Health Organization; 2010. World Health Organization. Treatment of tuberculosis: guidelines. Geneva: World Health Organization; 2010.
8.
go back to reference Fauce KB, Jameson HL. In: Kasper DL, Fauci AS, Longo DL, Braunwald E, Hauser SL, Jameson JL, editors. Harrison’s principles of Internal Medicine. In tuberculosis,16 edn. USA: McGraw-Hill companies Medical publishing division; 2005. p. 2783. Fauce KB, Jameson HL. In: Kasper DL, Fauci AS, Longo DL, Braunwald E, Hauser SL, Jameson JL, editors. Harrison’s principles of Internal Medicine. In tuberculosis,16 edn. USA: McGraw-Hill companies Medical publishing division; 2005. p. 2783.
9.
go back to reference Mori T, Uchimura K, Shimao T. Impact of introducing rifampicin for the treatment of tuberculosis during the 1970's in Japan. Kekkaku [Tuberculosis]. 2013;88(4):417–22. Mori T, Uchimura K, Shimao T. Impact of introducing rifampicin for the treatment of tuberculosis during the 1970's in Japan. Kekkaku [Tuberculosis]. 2013;88(4):417–22.
10.
go back to reference World Health Organization. WHO tuberculosis control program: Framework for effective tuberculosis control. 1994. World Health Organization. WHO tuberculosis control program: Framework for effective tuberculosis control. 1994.
11.
go back to reference Federal Ministry of Health of Ethiopia. Guidelines for clinical and programmatic management of TB, Leprosy and TB/HIV in Ethiopia. 5th ed. Addis Ababa: Ethiopian Federal Ministry of Health; 2012. Federal Ministry of Health of Ethiopia. Guidelines for clinical and programmatic management of TB, Leprosy and TB/HIV in Ethiopia. 5th ed. Addis Ababa: Ethiopian Federal Ministry of Health; 2012.
12.
go back to reference Manabe YC, Hermans SM, Lamorde M, Castelnuovo B, Mullins CD, Kuznik A. Rifampicin for continuation phase tuberculosis treatment in Uganda: a cost-effectiveness analysis. PLoS One. 2012;7(6):e39187.CrossRefPubMedPubMedCentral Manabe YC, Hermans SM, Lamorde M, Castelnuovo B, Mullins CD, Kuznik A. Rifampicin for continuation phase tuberculosis treatment in Uganda: a cost-effectiveness analysis. PLoS One. 2012;7(6):e39187.CrossRefPubMedPubMedCentral
13.
go back to reference Menzies D, Benedetti A, Paydar A, Martin I, Royce S, Pai M, Vernon A, Lienhardt C, Burman W. Effect of duration and intermittency of rifampin on tuberculosis treatment outcomes: a systematic review and meta-analysis. PLoS Med. 2009;6(9):e1000146.CrossRefPubMedPubMedCentral Menzies D, Benedetti A, Paydar A, Martin I, Royce S, Pai M, Vernon A, Lienhardt C, Burman W. Effect of duration and intermittency of rifampin on tuberculosis treatment outcomes: a systematic review and meta-analysis. PLoS Med. 2009;6(9):e1000146.CrossRefPubMedPubMedCentral
14.
go back to reference Ukwaja KN, Oshi SN, Alobu I, Oshi DC. Six- vs. eight-month anti-tuberculosis regimen for pulmonary tuberculosis under programme conditions. Int J Tuberc Lung Dis. 2015;19(3):295–301. i-vii.CrossRefPubMed Ukwaja KN, Oshi SN, Alobu I, Oshi DC. Six- vs. eight-month anti-tuberculosis regimen for pulmonary tuberculosis under programme conditions. Int J Tuberc Lung Dis. 2015;19(3):295–301. i-vii.CrossRefPubMed
15.
go back to reference Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946–1986, with relevant subsequent publications. Int J Tuberc Lung Dis. 1999;3:231–79. Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946–1986, with relevant subsequent publications. Int J Tuberc Lung Dis. 1999;3:231–79.
16.
go back to reference Federal Democratic Republic of Ethiopia Central Statistical Agency. Population Projection of Ethiopia for All Regions At Wereda Level from 2014 – 2017. Addis Ababa: CSA; 2013. Federal Democratic Republic of Ethiopia Central Statistical Agency. Population Projection of Ethiopia for All Regions At Wereda Level from 2014 – 2017. Addis Ababa: CSA; 2013.
17.
go back to reference Federal Ministry of Health of Ethiopia. Annual performance report. In: Health sector development programme iv. Addis Ababa: Federal Ministry of Health; 2011. Federal Ministry of Health of Ethiopia. Annual performance report. In: Health sector development programme iv. Addis Ababa: Federal Ministry of Health; 2011.
18.
go back to reference World Health Organization. Global tuberculosis report. In. France: WHO; 2013. World Health Organization. Global tuberculosis report. In. France: WHO; 2013.
19.
go back to reference Federal Ministry of Health of Ethiopia. Tuberculosis, Leprosy and TB/HIV Prevention and Control Programme Manual. 4th ed. Addis Ababa: Ministry of Health of Ethiopia; 2008. Federal Ministry of Health of Ethiopia. Tuberculosis, Leprosy and TB/HIV Prevention and Control Programme Manual. 4th ed. Addis Ababa: Ministry of Health of Ethiopia; 2008.
20.
go back to reference Southern Nation Nationalities Peoples Region Health Bureau (2014). "Health profile of Southern Nation Nationalities Peoples Region." Tuberculosis. 2015, from http://www.SNNPRHB.gov.et. Accessed 28 Oct 2015. Southern Nation Nationalities Peoples Region Health Bureau (2014). "Health profile of Southern Nation Nationalities Peoples Region." Tuberculosis. 2015, from http://​www.​SNNPRHB.​gov.​et. Accessed 28 Oct 2015.
22.
go back to reference World Health Organization. Definitions and reporting framework for tuberculosis – 2013 revision. In. Switzerland: WHO Library Cataloguing-in-Publication Data; 2013. World Health Organization. Definitions and reporting framework for tuberculosis – 2013 revision. In. Switzerland: WHO Library Cataloguing-in-Publication Data; 2013.
23.
go back to reference StataCorp. Stata: Release 13. Statistical Software. 13th ed. College Station: StataCorp LP; 2011. StataCorp. Stata: Release 13. Statistical Software. 13th ed. College Station: StataCorp LP; 2011.
24.
go back to reference Tessema B, Muche A, Bekele A, Reissig D, Emmrich F, Sack U. Treatment outcome of tuberculosis patients at Gondar University Teaching Hospital, Northwest Ethiopia. A five - year retrospective study. BMC Public Health. 2009;9:371.CrossRefPubMedPubMedCentral Tessema B, Muche A, Bekele A, Reissig D, Emmrich F, Sack U. Treatment outcome of tuberculosis patients at Gondar University Teaching Hospital, Northwest Ethiopia. A five - year retrospective study. BMC Public Health. 2009;9:371.CrossRefPubMedPubMedCentral
25.
go back to reference Munoz-Sellart M, Cuevas LE, Tumato M, Merid Y, Yassin MA. Factors associated with poor tuberculosis treatment outcome in the Southern Region of Ethiopia. Int J Tuberc Lung Dis. 2010;14(8):973–9.PubMed Munoz-Sellart M, Cuevas LE, Tumato M, Merid Y, Yassin MA. Factors associated with poor tuberculosis treatment outcome in the Southern Region of Ethiopia. Int J Tuberc Lung Dis. 2010;14(8):973–9.PubMed
26.
go back to reference Berhe G, Enquselassie F, Assefa A. Treatment outcome of smear-positive pulmonary tuberculosis patients in Tigray Region, Northern Ethiopia. BMC Public Health. 2012;12:537.CrossRefPubMedPubMedCentral Berhe G, Enquselassie F, Assefa A. Treatment outcome of smear-positive pulmonary tuberculosis patients in Tigray Region, Northern Ethiopia. BMC Public Health. 2012;12:537.CrossRefPubMedPubMedCentral
27.
go back to reference Feng J-Y, Su W-J, Chiu Y-C, Huang S-F, Lin Y-Y, Huang R-M, Lin C-H, Hwang J-J, Lee J-J, Yu M-C, et al. Initial presentations predict mortality in pulmonary tuberculosis patients - a prospective observational study. PloS One. 2011;6(9). Feng J-Y, Su W-J, Chiu Y-C, Huang S-F, Lin Y-Y, Huang R-M, Lin C-H, Hwang J-J, Lee J-J, Yu M-C, et al. Initial presentations predict mortality in pulmonary tuberculosis patients - a prospective observational study. PloS One. 2011;6(9).
28.
go back to reference Wang CS, Chen HC, Yang CJ, Wang WY, Chong IW, Hwang JJ, Huang MS. The impact of age on the demographic, clinical, radiographic characteristics and treatment outcomes of pulmonary tuberculosis patients in Taiwan. Infection. 2008;36(4):335–40.CrossRefPubMed Wang CS, Chen HC, Yang CJ, Wang WY, Chong IW, Hwang JJ, Huang MS. The impact of age on the demographic, clinical, radiographic characteristics and treatment outcomes of pulmonary tuberculosis patients in Taiwan. Infection. 2008;36(4):335–40.CrossRefPubMed
29.
go back to reference Kayigamba FR, Bakker MI, Mugisha V, Gasana M, Schim van der Loeff MF. Sputum completion and conversion rates after intensive phase of tuberculosis treatment: an assessment of the Rwandan control program. BMC Res Notes. 2012;5(357). Kayigamba FR, Bakker MI, Mugisha V, Gasana M, Schim van der Loeff MF. Sputum completion and conversion rates after intensive phase of tuberculosis treatment: an assessment of the Rwandan control program. BMC Res Notes. 2012;5(357).
30.
go back to reference Bernabe-Ortiz A, Carcamo CP, Sanchez JF, Rios J. Weight variation over time and its association with tuberculosis treatment outcome: a longitudinal analysis. PLoS One. 2011;6(4). Bernabe-Ortiz A, Carcamo CP, Sanchez JF, Rios J. Weight variation over time and its association with tuberculosis treatment outcome: a longitudinal analysis. PLoS One. 2011;6(4).
31.
go back to reference Hoa NB, Lauritsen JM, Rieder HL. Changes in body weight and tuberculosis treatment outcome in Viet Nam. Int J Tuberc Lung Dis. 2013;17(1):61–6.CrossRefPubMed Hoa NB, Lauritsen JM, Rieder HL. Changes in body weight and tuberculosis treatment outcome in Viet Nam. Int J Tuberc Lung Dis. 2013;17(1):61–6.CrossRefPubMed
32.
go back to reference Horne DJ, Royce SE, Gooze L, Narita M, Hopewell PC, Nahid P, Steingart KR. Sputum monitoring during tuberculosis treatment for predicting outcome: a systematic review and meta-analysis. Lancet Infect Dis. 2010;10(6):387–94.CrossRefPubMedPubMedCentral Horne DJ, Royce SE, Gooze L, Narita M, Hopewell PC, Nahid P, Steingart KR. Sputum monitoring during tuberculosis treatment for predicting outcome: a systematic review and meta-analysis. Lancet Infect Dis. 2010;10(6):387–94.CrossRefPubMedPubMedCentral
33.
go back to reference Daniel OJ, Alausa OK. Treatment outcome of TB/HIV positive and TB/HIV negative patients on directly observed treatment, short course (DOTS) in Sagamu, Nigeria. Niger J Med. 2006;15(3):222–6.PubMed Daniel OJ, Alausa OK. Treatment outcome of TB/HIV positive and TB/HIV negative patients on directly observed treatment, short course (DOTS) in Sagamu, Nigeria. Niger J Med. 2006;15(3):222–6.PubMed
34.
go back to reference Shaweno D, Worku A. Tuberculosis treatment survival of HIV positive TB patients on directly observed treatment short-course in Southern Ethiopia: a retrospective cohort study. BMC Res Notes. 2012;5:682.CrossRefPubMedPubMedCentral Shaweno D, Worku A. Tuberculosis treatment survival of HIV positive TB patients on directly observed treatment short-course in Southern Ethiopia: a retrospective cohort study. BMC Res Notes. 2012;5:682.CrossRefPubMedPubMedCentral
35.
go back to reference Maher D, Harries A, Getahun H. Tuberculosis and HIV interaction in sub-Saharan Africa: impact on patients and programmes; implications for policies. Trop Med Int Health. 2005;10(8):734–42.CrossRefPubMed Maher D, Harries A, Getahun H. Tuberculosis and HIV interaction in sub-Saharan Africa: impact on patients and programmes; implications for policies. Trop Med Int Health. 2005;10(8):734–42.CrossRefPubMed
36.
go back to reference World Health Organization. WHO policy on collaborative TB/HIV activities Guidelines for national programmes and other stakeholders. Italy: WHO Library Cataloguing-in-Publication Data; 2012. World Health Organization. WHO policy on collaborative TB/HIV activities Guidelines for national programmes and other stakeholders. Italy: WHO Library Cataloguing-in-Publication Data; 2012.
37.
go back to reference Uyei J, Coetzee D, Macinko J, Guttmacher S. Integrated delivery of HIV and tuberculosis services in sub-Saharan Africa: a systematic review. Lancet Infect Dis. 2011;11:855–67.CrossRefPubMed Uyei J, Coetzee D, Macinko J, Guttmacher S. Integrated delivery of HIV and tuberculosis services in sub-Saharan Africa: a systematic review. Lancet Infect Dis. 2011;11:855–67.CrossRefPubMed
Metadata
Title
Tuberculosis treatment outcomes of six and eight month treatment regimens in districts of Southwestern Ethiopia: a comparative cross-sectional study
Authors
Abyot Asres
Degu Jerene
Wakgari Deressa
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2016
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-016-1917-0

Other articles of this Issue 1/2016

BMC Infectious Diseases 1/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.